A sulfated plasma protein with a MW of approximately 66kDa that resembles ANTITHROMBIN III. The protein is an inhibitor of thrombin in plasma and is activated by dermatan sulfate or heparin. It is a member of the serpin superfamily.
A naturally occurring glycosaminoglycan found mostly in the skin and in connective tissue. It differs from CHONDROITIN SULFATE A (see CHONDROITIN SULFATES) by containing IDURONIC ACID in place of glucuronic acid, its epimer, at carbon atom 5. (from Merck, 12th ed)
Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins.
An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN.
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
Heteropolysaccharides which contain an N-acetylated hexosamine in a characteristic repeating disaccharide unit. The repeating structure of each disaccharide involves alternate 1,4- and 1,3-linkages consisting of either N-acetylglucosamine or N-acetylgalactosamine.
An absence or reduced level of Antithrombin III leading to an increased risk for thrombosis.
Clotting time of PLASMA mixed with a THROMBIN solution. It is a measure of the conversion of FIBRINOGEN to FIBRIN, which is prolonged by AFIBRINOGENEMIA, abnormal fibrinogen, or the presence of inhibitory substances, e.g., fibrin-fibrinogen degradation products, or HEPARIN. BATROXOBIN, a thrombin-like enzyme unaffected by the presence of heparin, may be used in place of thrombin.
Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES.
Activated form of factor X that participates in both the intrinsic and extrinsic pathways of blood coagulation. It catalyzes the conversion of prothrombin to thrombin in conjunction with other cofactors.
Enzymes which catalyze the elimination of delta-4,5-D-glucuronate residues from polysaccharides containing 1,4-beta-hexosaminyl and 1,3-beta-D-glucuronosyl or 1,3-alpha-L-iduronosyl linkages thereby bringing about depolymerization. EC 4.2.2.4 acts on chondroitin sulfate A and C as well as on dermatan sulfate and slowly on hyaluronate. EC 4.2.2.5 acts on chondroitin sulfate A and C.
Single-chain polypeptides of about 65 amino acids (7 kDa) from LEECHES that have a neutral hydrophobic N terminus, an acidic hydrophilic C terminus, and a compact, hydrophobic core region. Recombinant hirudins lack tyr-63 sulfation and are referred to as 'desulfato-hirudins'. They form a stable non-covalent complex with ALPHA-THROMBIN, thereby abolishing its ability to cleave FIBRINOGEN.
Agents that prevent clotting.
The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.
A class of Echinodermata characterized by long, slender bodies.
A mucopolysaccharide constituent of chondrin. (Grant & Hackh's Chemical Dictionary, 5th ed)
Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.
A subphylum of chordates intermediate between the invertebrates and the true vertebrates. It includes the Ascidians.
The rate dynamics in chemical or physical systems.
The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot.
Sepharose is a brand name for a type of cross-linked agarose gel beads used as a matrix in chromatography and other biochemical procedures, known for their high porosity, mechanical stability, and low non-specific binding, making them suitable for various purification and analytical applications.
A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia.
Polysaccharides are complex carbohydrates consisting of long, often branched chains of repeating monosaccharide units joined together by glycosidic bonds, which serve as energy storage molecules (e.g., glycogen), structural components (e.g., cellulose), and molecular recognition sites in various biological systems.
A family of serine proteinase inhibitors which are similar in amino acid sequence and mechanism of inhibition, but differ in their specificity toward proteolytic enzymes. This family includes alpha 1-antitrypsin, angiotensinogen, ovalbumin, antiplasmin, alpha 1-antichymotrypsin, thyroxine-binding protein, complement 1 inactivators, antithrombin III, heparin cofactor II, plasminogen inactivators, gene Y protein, placental plasminogen activator inhibitor, and barley Z protein. Some members of the serpin family may be substrates rather than inhibitors of SERINE ENDOPEPTIDASES, and some serpins occur in plants where their function is not known.
Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).
Inorganic salts of sulfuric acid.
The parts of a macromolecule that directly participate in its specific combination with another molecule.
Proteins prepared by recombinant DNA technology.
A serine endopeptidase secreted by the pancreas as its zymogen, CHYMOTRYPSINOGEN and carried in the pancreatic juice to the duodenum where it is activated by TRYPSIN. It selectively cleaves aromatic amino acids on the carboxyl side.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot.
Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.

Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. (1/122)

Assembly of ternary thrombin-heparin-fibrin complexes, formed when fibrin binds to exosite 1 on thrombin and fibrin-bound heparin binds to exosite 2, produces a 58- and 247-fold reduction in the heparin-catalyzed rate of thrombin inhibition by antithrombin and heparin cofactor II, respectively. The greater reduction for heparin cofactor II reflects its requirement for access to exosite 1 during the inhibitory process. Protection from inhibition by antithrombin and heparin cofactor II requires ligation of both exosites 1 and 2 because minimal protection is seen when exosite 1 variants (gamma-thrombin and thrombin Quick 1) or an exosite 2 variant (Arg93 --> Ala, Arg97 --> Ala, and Arg101 --> Ala thrombin) is substituted for thrombin. Likewise, the rate of thrombin inhibition by the heparin-independent inhibitor, alpha1-antitrypsin Met358 --> Arg, is decreased less than 2-fold in the presence of soluble fibrin and heparin. In contrast, thrombin is protected from inhibition by a covalent antithrombin-heparin complex, suggesting that access of heparin to exosite 2 of thrombin is hampered when ternary complex formation occurs. These results reveal the importance of exosites 1 and 2 of thrombin in assembly of the ternary complex and the subsequent protection of thrombin from inhibition by heparin-catalyzed inhibitors.  (+info)

Amino acid residues of heparin cofactor II required for stimulation of thrombin inhibition by sulphated polyanions. (2/122)

A variety of sulphated polyanions in addition to heparin and dermatan sulphate stimulate the inhibition of thrombin by heparin cofactor II (HCII). Previous investigations indicated that the binding sites on HCII for heparin and dermatan sulphate overlap but are not identical. In this study we determined the concentrations (IC50) of various polyanions required to stimulate thrombin inhibition by native recombinant HCII in comparison with three recombinant HCII variants having decreased affinity for heparin (Lys-173-->Gln), dermatan sulphate (Arg-189-->His), or both heparin and dermatan sulphate (Lys-185-->Asn). Pentosan polysulphate, sulphated bis-lactobionic acid amide, and sulphated bis-maltobionic acid amide resembled dermatan sulphate, since their IC50 values were increased to a much greater degree (>/=8-fold) by the mutations Arg-189-->His and Lys-185-->Asn than by Lys-173-->Gln (Gln and Lys-185-->Asn (>/=6-fold) than by Arg-189-->His (+info)

Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor II. (3/122)

Heparin and dermatan sulfate activate heparin cofactor II (HCII) comparably, presumably by liberating the amino terminus of HCII to bind to exosite I of thrombin. To explore this model of activation, we systematically substituted basic residues in the glycosaminoglycan-binding domain of HCII with neutral amino acids and measured the rates of thrombin inactivation by the mutants. Mutant D, with changes at Arg(184), Lys(185), Arg(189), Arg(192), Arg(193), demonstrated a approximately 130-fold increased rate of thrombin inactivation that was unaffected by the presence of glycosaminoglycans. The increased rate reflects displacement of the amino terminus of mutant D because (a) mutant D inactivates gamma-thrombin at a 65-fold slower rate than alpha-thrombin, (b) hirudin-(54-65) decreases the rate of thrombin inactivation, and (c) deletion of the amino terminus of mutant D reduces the rate of thrombin inactivation approximately 100-fold. We also examined the contribution of glycosaminoglycan-mediated bridging of thrombin to HCII to the inhibitory process. Whereas activation of HCII by heparin was chain-length dependent, stimulation by dermatan sulfate was not, suggesting that dermatan sulfate does not utilize a template mechanism to accelerate the inhibitory process. Fluorescence spectroscopy revealed that dermatan sulfate evokes greater conformational changes in HCII than heparin, suggesting that dermatan sulfate stimulates HCII by producing more effective displacement of the amino terminus.  (+info)

Enhancement of heparin cofactor II anticoagulant activity. (4/122)

Heparin cofactor II (HCII) is a serpin whose thrombin inhibition activity is accelerated by glycosaminoglycans. We describe the novel properties of a carboxyl-terminal histidine-tagged recombinant HCII (rHCII-CHis(6)). Thrombin inhibition by rHCII-CHis(6) was increased >2-fold at approximately 5 microgram/ml heparin compared with wild-type recombinant HCII (wt-rHCII) at 50-100 microgram/ml heparin. Enhanced activity of rHCII-CHis(6) was reversed by treatment with carboxypeptidase A. We assessed the role of the HCII acidic domain by constructing amino-terminal deletion mutants (Delta1-52, Delta1-68, and Delta1-75) in wt-rHCII and rHCII-CHis(6). Without glycosaminoglycan, unlike wt-rHCII deletion mutants, the rHCII-CHis(6) deletion mutants were less active compared with full-length rHCII-CHis(6). With glycosaminoglycans, Delta1-68 and Delta1-75 rHCIIs were all less active. We assessed the character of the tag by comparing rHCII-CHis(6), rHCII-CAla(6), and rHCII-CLys(6) to wt-rHCII. Only rHCII-CHis(6) had increased activity with heparin, whereas all three mutants have increased heparin binding. We generated a carboxyl-terminal histidine-tagged recombinant antithrombin III to study the tag on another serpin. Interestingly, this mutant antithrombin III had reduced heparin cofactor activity compared with wild-type protein. In a plasma-based assay, the glycosaminoglycan-dependent inhibition of thrombin by rHCII-CHis(6) was significantly greater compared with wt-rHCII. Thus, HCII variants with increased function, such as rHCII-CHis(6), may offer novel reagents for clinical application.  (+info)

Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human atherosclerotic plaque. (5/122)

Biglycan and decorin are small dermatan sulfate-containing proteoglycans in the extracellular matrix of the artery wall. The dermatan sulfate chains are known to stimulate thrombin inhibition by heparin cofactor II (HCII), a plasma proteinase inhibitor that has been detected within the artery wall. The purpose of this study was to analyze the HCII-stimulatory activity of biglycan and decorin isolated from normal human aorta and atherosclerotic lesions type II through VI and to correlate activity with dermatan sulfate chain composition and structure. Biglycan and decorin from plaque exhibited a 24-75% and 38-79% loss of activity, respectively, in thrombin-HCII inhibition assays relative to proteoglycan from normal aorta. A significant negative linear relationship was observed between lesion severity and HCII stimulatory activity (r = 0.79, biglycan; r = 0.63, decorin; p < 0.05). Biglycan, but not decorin, from atherosclerotic plaque contained significantly reduced amounts of iduronic acid and disulfated disaccharides DeltaDi-2,4S and DeltaDi-4,6S relative to proteoglycan from normal artery. Affinity coelectrophoresis analysis of a subset of samples demonstrated that increased interaction of proteoglycan with HCII in agarose gels paralleled increased activity in thrombin-HCII inhibition assays. In conclusion, both biglycan and decorin from atherosclerotic plaque possessed reduced activity with HCII, but only biglycan demonstrated a correlation between activity and specific glycosaminoglycan structural features. Loss of the ability of biglycan and decorin in atherosclerotic lesions to regulate thrombin activity through HCII may be critical in the progression of the disease.  (+info)

Activation of heparin cofactor II by calcium spirulan. (6/122)

Heparin cofactor II (HCII) is a plasma serine protease inhibitor whose ability to inhibit alpha-thrombin is accelerated by a variety of sulfated polysaccharides in addition to heparin and dermatan sulfate. Previous investigations have indicated that calcium spirulan (Ca-SP), a novel sulfated polysaccharide, enhanced the rate of inhibition of alpha-thrombin by HCII. In this study, we investigated the mechanism of the activation of HCII by Ca-SP. Interestingly, in the presence of Ca-SP, an N-terminal deletion mutant of HCII (rHCII-Delta74) inhibited alpha-thrombin, as native recombinant HCII (native rHCII) did. The second-order rate constant for the inhibition of alpha-thrombin by rHCII-Delta74 was 2.0 x 10(8) M(-1) min(-1) in the presence of 50 microgram/ml Ca-SP and 10, 000-fold higher than in the absence of Ca-SP. The rates of native rHCII and rHCII-Delta74 for the inhibition of gamma-thrombin were increased only 80- and 120-fold, respectively. Our results suggested that the anion-binding exosite I of alpha-thrombin was essential for the rapid inhibition reaction by HCII in the presence of Ca-SP and that the N-terminal acidic domain of HCII was not required. Therefore, we proposed a mechanism by which HCII was activated allosterically by Ca-SP and could interact with the anion-binding exosite I of thrombin not through the N-terminal acidic domain of HCII. The Arg(103) --> Leu mutant bound to Ca-SP-Toyopearl with normal affinity and inhibited alpha-thrombin in a manner similar to native rHCII. These results indicate that Arg(103) in HCII molecule is not critical for the interaction with Ca-SP.  (+info)

Effect of oligodeoxynucleotide thrombin aptamer on thrombin inhibition by heparin cofactor II and antithrombin. (7/122)

'Thrombin aptamers' are based on the 15-nucleotide consensus sequence of d(GGTTGGTGTGGTTGG) that binds specifically to thrombin's anion-binding exosite-I. The effect of aptamer-thrombin interactions during inhibition by the serine protease inhibitor (serpin) heparin cofactor II (HCII) and antithrombin (AT) has not been described. Thrombin inhibition by HCII without glycosaminoglycan was decreased approximately two-fold by the aptamer. In contrast, the aptamer dramatically reduced thrombin inhibition by >200-fold and 30-fold for HCII-heparin and HCII-dermatan sulfate, respectively. The aptamer had essentially no effect on thrombin inhibition by AT with or without heparin. These results add to our understanding of thrombin aptamer activity for potential clinical application, and they further demonstrate the importance of thrombin exosite-I during inhibition by HCII-glycosaminoglycans.  (+info)

Inhibition of thrombin by sulfated polysaccharides isolated from green algae. (8/122)

Eight different sulfated polysaccharides were isolated from Chlorophyta. All exhibited thrombin inhibition through a heparin cofactor II (HCII)-dependent pathway, and their effects on the inhibition of thrombin were more potent than those of heparin or dermatan sulfate. In particular, remarkably potent thrombin inhibition was found for the sulfated polysaccharides isolated from the Codiales. In the presence of these sulfated polysaccharides, both the recombinant HCII (rHCII) variants Lys(173)-->Leu and Arg(189)-->His, which are defective in interactions with heparin and dermatan sulfate, respectively, inhibited thrombin in a manner similar to native rHCII. This result indicates that the binding site of HCII for each of these eight sulfated polysaccharides is different from the heparin- or dermatan sulfate-binding site. All the sulfated polysaccharides but RS-2 significantly stimulated the inhibition of thrombin by an N-terminal deletion mutant of HCII (rHCII-Delta74). Furthermore, hirudin(54-65) decreased only 2-5-fold the rate of thrombin inhibition by HCII stimulated by the sulfated polysaccharides, while HD22, a single-stranded DNA aptamer that binds exosite II of thrombin, produced an approximately 10-fold reduction in this rate. These results suggest that, unlike heparin and dermatan sulfate, the sulfated polysaccharides isolated from Chlorophyta activate HCII primarily by an allosteric mechanism different from displacement and template mechanisms.  (+info)

Heparin Cofactor II (HCII), also known as serine protease inhibitor E2 or labile factor, is a member of the serpin family of proteins. It is primarily produced in the liver and secreted into the bloodstream. HCII functions as a anticoagulant protein by inhibiting certain serine proteases involved in the coagulation cascade, particularly thrombin and factor Xa. The inhibitory activity of HCII is greatly enhanced in the presence of heparin or other glycosaminoglycans, hence its name.

HCII plays a crucial role in regulating blood clotting by controlling the levels of active thrombin and factor Xa in the circulation, thereby preventing excessive clot formation and maintaining normal hemostasis. Deficiencies or dysfunctions in HCII have been associated with an increased risk of thrombosis and other coagulation-related disorders.

Dermatan sulfate is a type of glycosaminoglycan, which is a long, unbranched sugar chain found on the proteoglycan core protein in the extracellular matrix of animal tissues. It is composed of repeating disaccharide units of iduronic acid and N-acetylgalactosamine, with alternating sulfation at the 4-position of the iduronic acid and the 6-position of the galactosamine.

Dermatan sulfate is found in various tissues, including skin, heart valves, and blood vessels, where it plays important roles in regulating cell behavior, tissue development, and homeostasis. It also binds to a variety of growth factors, cytokines, and enzymes, modulating their activities and contributing to the regulation of various biological processes.

Abnormalities in dermatan sulfate metabolism can lead to several genetic disorders, such as Hunter syndrome and Hurler-Scheie syndrome, which are characterized by skeletal abnormalities, cardiac defects, and neurological impairment.

Antithrombins are substances that prevent the formation or promote the dissolution of blood clots (thrombi). They include:

1. Anticoagulants: These are medications that reduce the ability of the blood to clot. Examples include heparin, warfarin, and direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and dabigatran.
2. Thrombolytic agents: These are medications that break down existing blood clots. Examples include alteplase, reteplase, and tenecteplase.
3. Fibrinolytics: These are a type of thrombolytic agent that specifically target fibrin, a protein involved in the formation of blood clots.
4. Natural anticoagulants: These are substances produced by the body to regulate blood clotting. Examples include antithrombin III, protein C, and protein S.

Antithrombins are used in the prevention and treatment of various thromboembolic disorders, such as deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction (heart attack). It is important to note that while antithrombins can help prevent or dissolve blood clots, they also increase the risk of bleeding, so their use must be carefully monitored.

Thrombin is a serine protease enzyme that plays a crucial role in the coagulation cascade, which is a complex series of biochemical reactions that leads to the formation of a blood clot (thrombus) to prevent excessive bleeding during an injury. Thrombin is formed from its precursor protein, prothrombin, through a process called activation, which involves cleavage by another enzyme called factor Xa.

Once activated, thrombin converts fibrinogen, a soluble plasma protein, into fibrin, an insoluble protein that forms the structural framework of a blood clot. Thrombin also activates other components of the coagulation cascade, such as factor XIII, which crosslinks and stabilizes the fibrin network, and platelets, which contribute to the formation and growth of the clot.

Thrombin has several regulatory mechanisms that control its activity, including feedback inhibition by antithrombin III, a plasma protein that inactivates thrombin and other serine proteases, and tissue factor pathway inhibitor (TFPI), which inhibits the activation of factor Xa, thereby preventing further thrombin formation.

Overall, thrombin is an essential enzyme in hemostasis, the process that maintains the balance between bleeding and clotting in the body. However, excessive or uncontrolled thrombin activity can lead to pathological conditions such as thrombosis, atherosclerosis, and disseminated intravascular coagulation (DIC).

Antithrombin III is a protein that inhibits the formation of blood clots (thrombi) in the body. It does this by inactivating several enzymes involved in coagulation, including thrombin and factor Xa. Antithrombin III is produced naturally by the liver and is also available as a medication for the prevention and treatment of thromboembolic disorders, such as deep vein thrombosis and pulmonary embolism. It works by binding to and neutralizing excess clotting factors in the bloodstream, thereby reducing the risk of clot formation.

Heparin is defined as a highly sulfated glycosaminoglycan (a type of polysaccharide) that is widely present in many tissues, but is most commonly derived from the mucosal tissues of mammalian lungs or intestinal mucosa. It is an anticoagulant that acts as an inhibitor of several enzymes involved in the blood coagulation cascade, primarily by activating antithrombin III which then neutralizes thrombin and other clotting factors.

Heparin is used medically to prevent and treat thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, and certain types of heart attacks. It can also be used during hemodialysis, cardiac bypass surgery, and other medical procedures to prevent the formation of blood clots.

It's important to note that while heparin is a powerful anticoagulant, it does not have any fibrinolytic activity, meaning it cannot dissolve existing blood clots. Instead, it prevents new clots from forming and stops existing clots from growing larger.

Glycosaminoglycans (GAGs) are long, unbranched polysaccharides composed of repeating disaccharide units. They are a major component of the extracellular matrix and connective tissues in the body. GAGs are negatively charged due to the presence of sulfate and carboxyl groups, which allows them to attract positively charged ions and water molecules, contributing to their ability to retain moisture and maintain tissue hydration and elasticity.

GAGs can be categorized into four main groups: heparin/heparan sulfate, chondroitin sulfate/dermatan sulfate, keratan sulfate, and hyaluronic acid. These different types of GAGs have varying structures and functions in the body, including roles in cell signaling, inflammation, and protection against enzymatic degradation.

Heparin is a highly sulfated form of heparan sulfate that is found in mast cells and has anticoagulant properties. Chondroitin sulfate and dermatan sulfate are commonly found in cartilage and contribute to its resiliency and ability to withstand compressive forces. Keratan sulfate is found in corneas, cartilage, and bone, where it plays a role in maintaining the structure and function of these tissues. Hyaluronic acid is a large, nonsulfated GAG that is widely distributed throughout the body, including in synovial fluid, where it provides lubrication and shock absorption for joints.

Antithrombin III (ATIII) deficiency is a genetic disorder that affects the body's ability to regulate blood clotting. ATIII is a protein produced in the liver that inhibits the activity of thrombin and other coagulation factors, preventing excessive clot formation.

People with ATIII deficiency have lower than normal levels of this protein, which can lead to an increased risk of developing abnormal blood clots (thrombosis) in veins, particularly deep vein thrombosis (DVT) and pulmonary embolism (PE). These clots can cause serious complications, including damage to the affected veins, organ damage, and even death.

ATIII deficiency can be classified into two types: type I and type II. Type I is characterized by a quantitative decrease in ATIII levels, while type II is characterized by a qualitative defect that results in reduced functional activity of the protein.

The condition is usually inherited in an autosomal dominant manner, meaning that a person has a 50% chance of inheriting the gene mutation from an affected parent. However, some cases may occur spontaneously due to new mutations in the ATIII gene. Treatment for ATIII deficiency typically involves anticoagulation therapy with medications such as heparin or warfarin to prevent blood clots from forming.

Thrombin time (TT) is a medical laboratory test that measures the time it takes for a clot to form after thrombin, an enzyme that converts fibrinogen to fibrin in the final step of the coagulation cascade, is added to a plasma sample. This test is used to evaluate the efficiency of the conversion of fibrinogen to fibrin and can be used to detect the presence of abnormalities in the coagulation system, such as the presence of heparin or dysfibrinogenemia. Increased thrombin time may indicate the presence of a systemic anticoagulant or a deficiency in fibrinogen.

Serine proteinase inhibitors, also known as serine protease inhibitors or serpins, are a group of proteins that inhibit serine proteases, which are enzymes that cut other proteins in a process called proteolysis. Serine proteinases are important in many biological processes such as blood coagulation, fibrinolysis, inflammation and cell death. The inhibition of these enzymes by serpin proteins is an essential regulatory mechanism to maintain the balance and prevent uncontrolled proteolytic activity that can lead to diseases.

Serpins work by forming a covalent complex with their target serine proteinases, irreversibly inactivating them. The active site of serpins contains a reactive center loop (RCL) that mimics the protease's target protein sequence and acts as a bait for the enzyme. When the protease cleaves the RCL, it gets trapped within the serpin structure, leading to its inactivation.

Serpin proteinase inhibitors play crucial roles in various physiological processes, including:

1. Blood coagulation and fibrinolysis regulation: Serpins such as antithrombin, heparin cofactor II, and protease nexin-2 control the activity of enzymes involved in blood clotting and dissolution to prevent excessive or insufficient clot formation.
2. Inflammation modulation: Serpins like α1-antitrypsin, α2-macroglobulin, and C1 inhibitor regulate the activity of proteases released during inflammation, protecting tissues from damage.
3. Cell death regulation: Some serpins, such as PI-9/SERPINB9, control apoptosis (programmed cell death) by inhibiting granzyme B, a protease involved in this process.
4. Embryonic development and tissue remodeling: Serpins like plasminogen activator inhibitor-1 (PAI-1) and PAI-2 regulate the activity of enzymes involved in extracellular matrix degradation during embryonic development and tissue remodeling.
5. Neuroprotection: Serpins such as neuroserpin protect neurons from damage by inhibiting proteases released during neuroinflammation or neurodegenerative diseases.

Dysregulation of serpins has been implicated in various pathological conditions, including thrombosis, emphysema, Alzheimer's disease, and cancer. Understanding the roles of serpins in these processes may provide insights into potential therapeutic strategies for treating these diseases.

Factor Xa is a serine protease that plays a crucial role in the coagulation cascade, which is a series of reactions that lead to the formation of a blood clot. It is one of the activated forms of Factor X, a pro-protein that is converted to Factor Xa through the action of other enzymes in the coagulation cascade.

Factor Xa functions as a key component of the prothrombinase complex, which also includes calcium ions, phospholipids, and activated Factor V (also known as Activated Protein C or APC). This complex is responsible for converting prothrombin to thrombin, which then converts fibrinogen to fibrin, forming a stable clot.

Inhibitors of Factor Xa are used as anticoagulants in the prevention and treatment of thromboembolic disorders such as deep vein thrombosis and pulmonary embolism. These drugs work by selectively inhibiting Factor Xa, thereby preventing the formation of the prothrombinase complex and reducing the risk of clot formation.

Chondroitin lyases are a group of enzymes that breakdown chondroitin, which is a type of proteoglycan found in connective tissues such as cartilage. These enzymes cleave chondroitin at specific points by removing certain sugar units, thereby breaking down the large, complex molecule into smaller fragments. Chondroitin lyases are classified based on their site of action and the type of fragment they produce. They play important roles in various biological processes, including tissue remodeling, growth, and development. In some cases, chondroitin lyases may also be used in research and medical settings to study the structure and function of proteoglycans or for the production of smaller chondroitin fragments with therapeutic potential.

Hirudin is not a medical term itself, but it is a specific substance with medical relevance. Hirudin is a naturally occurring anticoagulant that is found in the saliva of certain species of leeches (such as Hirudo medicinalis). This compound works by inhibiting the activity of thrombin, a key enzyme in the coagulation cascade, which ultimately results in preventing blood clot formation.

Medically, hirudin has been used in some research and therapeutic settings for its anticoagulant properties. For instance, recombinant hirudin (also known as lepirudin) is available for clinical use as an injectable anticoagulant to treat or prevent blood clots in specific medical conditions, such as heparin-induced thrombocytopenia (HIT).

In summary, Hirudins are a group of anticoagulant substances, primarily derived from leeches, that inhibit the activity of thrombin and have potential medical applications in preventing or treating blood clots.

Anticoagulants are a class of medications that work to prevent the formation of blood clots in the body. They do this by inhibiting the coagulation cascade, which is a series of chemical reactions that lead to the formation of a clot. Anticoagulants can be given orally, intravenously, or subcutaneously, depending on the specific drug and the individual patient's needs.

There are several different types of anticoagulants, including:

1. Heparin: This is a naturally occurring anticoagulant that is often used in hospitalized patients who require immediate anticoagulation. It works by activating an enzyme called antithrombin III, which inhibits the formation of clots.
2. Low molecular weight heparin (LMWH): LMWH is a form of heparin that has been broken down into smaller molecules. It has a longer half-life than standard heparin and can be given once or twice daily by subcutaneous injection.
3. Direct oral anticoagulants (DOACs): These are newer oral anticoagulants that work by directly inhibiting specific clotting factors in the coagulation cascade. Examples include apixaban, rivaroxaban, and dabigatran.
4. Vitamin K antagonists: These are older oral anticoagulants that work by inhibiting the action of vitamin K, which is necessary for the formation of clotting factors. Warfarin is an example of a vitamin K antagonist.

Anticoagulants are used to prevent and treat a variety of conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation, and prosthetic heart valve thrombosis. It is important to note that anticoagulants can increase the risk of bleeding, so they must be used with caution and regular monitoring of blood clotting times may be required.

Partial Thromboplastin Time (PTT) is a medical laboratory test that measures the time it takes for blood to clot. It's more specifically a measure of the intrinsic and common pathways of the coagulation cascade, which are the series of chemical reactions that lead to the formation of a clot.

The test involves adding a partial thromboplastin reagent (an activator of the intrinsic pathway) and calcium to plasma, and then measuring the time it takes for a fibrin clot to form. This is compared to a control sample, and the ratio of the two times is calculated.

The PTT test is often used to help diagnose bleeding disorders or abnormal blood clotting, such as hemophilia or disseminated intravascular coagulation (DIC). It can also be used to monitor the effectiveness of anticoagulant therapy, such as heparin. Prolonged PTT results may indicate a bleeding disorder or an increased risk of bleeding, while shortened PTT results may indicate a hypercoagulable state and an increased risk of thrombosis.

I'm sorry for any confusion, but the term "Sea Cucumbers" is not typically used in medical definitions. It is a common name given to marine animals belonging to the class Holothuroidea in the phylum Echinodermata. These are sausage-shaped, bottom-dwelling creatures found on the sea floor worldwide. They have a leathery skin and a set of tube feet used for locomotion. While they have some cultural and commercial importance in parts of the world, they do not have direct relevance to medical definitions.

Chondroitin is a type of molecule known as a glycosaminoglycan, which is found in the connective tissues of the body, including cartilage. It is a major component of proteoglycans, which are complex molecules that provide structural support and help retain water within the cartilage, allowing it to function as a cushion between joints.

Chondroitin sulfate, a form of chondroitin, is commonly used in dietary supplements for osteoarthritis, a condition characterized by the breakdown of cartilage in joints. The idea behind using chondroitin sulfate as a treatment for osteoarthritis is that it may help to rebuild damaged cartilage and reduce inflammation in the affected joints. However, research on the effectiveness of chondroitin sulfate for osteoarthritis has had mixed results, with some studies showing modest benefits while others have found no significant effects.

It's important to note that dietary supplements containing chondroitin are not regulated by the U.S. Food and Drug Administration (FDA) in the same way that drugs are, so the quality and purity of these products can vary widely. As with any supplement, it's a good idea to talk to your doctor before starting to take chondroitin, especially if you have any medical conditions or are taking other medications.

Glycoproteins are complex proteins that contain oligosaccharide chains (glycans) covalently attached to their polypeptide backbone. These glycans are linked to the protein through asparagine residues (N-linked) or serine/threonine residues (O-linked). Glycoproteins play crucial roles in various biological processes, including cell recognition, cell-cell interactions, cell adhesion, and signal transduction. They are widely distributed in nature and can be found on the outer surface of cell membranes, in extracellular fluids, and as components of the extracellular matrix. The structure and composition of glycoproteins can vary significantly depending on their function and location within an organism.

Urochordata is a phylum in the animal kingdom that includes sessile, marine organisms commonly known as tunicates or sea squirts. The name "Urochordata" means "tail-cord animals," which refers to the notochord, a flexible, rod-like structure found in the tails of these animals during their larval stage.

Tunicates are filter feeders that draw water into their bodies through a siphon and extract plankton and other organic particles for nutrition. They have a simple body plan, consisting of a protective outer covering called a tunic, an inner body mass with a muscular pharynx, and a tail-like structure called the post-anal tail.

Urochordates are of particular interest to biologists because they are considered to be the closest living relatives to vertebrates (animals with backbones), sharing a common ancestor with them around 550 million years ago. Despite their simple appearance, tunicates have complex developmental processes that involve the formation of notochords, dorsal nerve cords, and other structures that are similar to those found in vertebrate embryos.

Overall, Urochordata is a fascinating phylum that provides important insights into the evolutionary history of animals and their diverse body plans.

In the context of medicine and pharmacology, "kinetics" refers to the study of how a drug moves throughout the body, including its absorption, distribution, metabolism, and excretion (often abbreviated as ADME). This field is called "pharmacokinetics."

1. Absorption: This is the process of a drug moving from its site of administration into the bloodstream. Factors such as the route of administration (e.g., oral, intravenous, etc.), formulation, and individual physiological differences can affect absorption.

2. Distribution: Once a drug is in the bloodstream, it gets distributed throughout the body to various tissues and organs. This process is influenced by factors like blood flow, protein binding, and lipid solubility of the drug.

3. Metabolism: Drugs are often chemically modified in the body, typically in the liver, through processes known as metabolism. These changes can lead to the formation of active or inactive metabolites, which may then be further distributed, excreted, or undergo additional metabolic transformations.

4. Excretion: This is the process by which drugs and their metabolites are eliminated from the body, primarily through the kidneys (urine) and the liver (bile).

Understanding the kinetics of a drug is crucial for determining its optimal dosing regimen, potential interactions with other medications or foods, and any necessary adjustments for special populations like pediatric or geriatric patients, or those with impaired renal or hepatic function.

Blood coagulation, also known as blood clotting, is a complex process that occurs in the body to prevent excessive bleeding when a blood vessel is damaged. This process involves several different proteins and chemical reactions that ultimately lead to the formation of a clot.

The coagulation cascade is initiated when blood comes into contact with tissue factor, which is exposed after damage to the blood vessel wall. This triggers a series of enzymatic reactions that activate clotting factors, leading to the formation of a fibrin clot. Fibrin is a protein that forms a mesh-like structure that traps platelets and red blood cells to form a stable clot.

Once the bleeding has stopped, the coagulation process is regulated and inhibited to prevent excessive clotting. The fibrinolytic system degrades the clot over time, allowing for the restoration of normal blood flow.

Abnormalities in the blood coagulation process can lead to bleeding disorders or thrombotic disorders such as deep vein thrombosis and pulmonary embolism.

Sepharose is not a medical term itself, but it is a trade name for a type of gel that is often used in medical and laboratory settings. Sepharose is a type of cross-linked agarose gel, which is derived from seaweed. It is commonly used in chromatography, a technique used to separate and purify different components of a mixture based on their physical or chemical properties.

Sepharose gels are available in various forms, including beads and sheets, and they come in different sizes and degrees of cross-linking. These variations allow for the separation and purification of molecules with different sizes, charges, and other properties. Sepharose is known for its high porosity, mechanical stability, and low non-specific binding, making it a popular choice for many laboratory applications.

Prothrombin is a protein present in blood plasma, and it's also known as coagulation factor II. It plays a crucial role in the coagulation cascade, which is a complex series of reactions that leads to the formation of a blood clot.

When an injury occurs, the coagulation cascade is initiated to prevent excessive blood loss. Prothrombin is converted into its active form, thrombin, by another factor called factor Xa in the presence of calcium ions, phospholipids, and factor Va. Thrombin then catalyzes the conversion of fibrinogen into fibrin, forming a stable clot.

Prothrombin levels can be measured through a blood test, which is often used to diagnose or monitor conditions related to bleeding or coagulation disorders, such as liver disease or vitamin K deficiency.

Polysaccharides are complex carbohydrates consisting of long chains of monosaccharide units (simple sugars) bonded together by glycosidic linkages. They can be classified based on the type of monosaccharides and the nature of the bonds that connect them.

Polysaccharides have various functions in living organisms. For example, starch and glycogen serve as energy storage molecules in plants and animals, respectively. Cellulose provides structural support in plants, while chitin is a key component of fungal cell walls and arthropod exoskeletons.

Some polysaccharides also have important roles in the human body, such as being part of the extracellular matrix (e.g., hyaluronic acid) or acting as blood group antigens (e.g., ABO blood group substances).

SERPINs are an acronym for "serine protease inhibitors." They are a group of proteins that inhibit serine proteases, which are enzymes that cut other proteins. SERPINs are found in various tissues and body fluids, including blood, and play important roles in regulating biological processes such as inflammation, blood clotting, and cell death. They do this by forming covalent complexes with their target proteases, thereby preventing them from carrying out their proteolytic activities. Mutations in SERPIN genes have been associated with several genetic disorders, including emphysema, cirrhosis, and dementia.

Protease inhibitors are a class of antiviral drugs that are used to treat infections caused by retroviruses, such as the human immunodeficiency virus (HIV), which is responsible for causing AIDS. These drugs work by blocking the activity of protease enzymes, which are necessary for the replication and multiplication of the virus within infected cells.

Protease enzymes play a crucial role in the life cycle of retroviruses by cleaving viral polyproteins into functional units that are required for the assembly of new viral particles. By inhibiting the activity of these enzymes, protease inhibitors prevent the virus from replicating and spreading to other cells, thereby slowing down the progression of the infection.

Protease inhibitors are often used in combination with other antiretroviral drugs as part of highly active antiretroviral therapy (HAART) for the treatment of HIV/AIDS. Common examples of protease inhibitors include saquinavir, ritonavir, indinavir, and atazanavir. While these drugs have been successful in improving the outcomes of people living with HIV/AIDS, they can also cause side effects such as nausea, diarrhea, headaches, and lipodystrophy (changes in body fat distribution).

In the context of medicine and biology, sulfates are ions or compounds that contain the sulfate group (SO4−2). Sulfate is a polyatomic anion with the structure of a sphere. It consists of a central sulfur atom surrounded by four oxygen atoms in a tetrahedral arrangement.

Sulfates can be found in various biological molecules, such as glycosaminoglycans and proteoglycans, which are important components of connective tissue and the extracellular matrix. Sulfate groups play a crucial role in these molecules by providing negative charges that help maintain the structural integrity and hydration of tissues.

In addition to their biological roles, sulfates can also be found in various medications and pharmaceutical compounds. For example, some laxatives contain sulfate salts, such as magnesium sulfate (Epsom salt) or sodium sulfate, which work by increasing the water content in the intestines and promoting bowel movements.

It is important to note that exposure to high levels of sulfates can be harmful to human health, particularly in the form of sulfur dioxide (SO2), a common air pollutant produced by burning fossil fuels. Prolonged exposure to SO2 can cause respiratory problems and exacerbate existing lung conditions.

In the context of medical and biological sciences, a "binding site" refers to a specific location on a protein, molecule, or cell where another molecule can attach or bind. This binding interaction can lead to various functional changes in the original protein or molecule. The other molecule that binds to the binding site is often referred to as a ligand, which can be a small molecule, ion, or even another protein.

The binding between a ligand and its target binding site can be specific and selective, meaning that only certain ligands can bind to particular binding sites with high affinity. This specificity plays a crucial role in various biological processes, such as signal transduction, enzyme catalysis, or drug action.

In the case of drug development, understanding the location and properties of binding sites on target proteins is essential for designing drugs that can selectively bind to these sites and modulate protein function. This knowledge can help create more effective and safer therapeutic options for various diseases.

Recombinant proteins are artificially created proteins produced through the use of recombinant DNA technology. This process involves combining DNA molecules from different sources to create a new set of genes that encode for a specific protein. The resulting recombinant protein can then be expressed, purified, and used for various applications in research, medicine, and industry.

Recombinant proteins are widely used in biomedical research to study protein function, structure, and interactions. They are also used in the development of diagnostic tests, vaccines, and therapeutic drugs. For example, recombinant insulin is a common treatment for diabetes, while recombinant human growth hormone is used to treat growth disorders.

The production of recombinant proteins typically involves the use of host cells, such as bacteria, yeast, or mammalian cells, which are engineered to express the desired protein. The host cells are transformed with a plasmid vector containing the gene of interest, along with regulatory elements that control its expression. Once the host cells are cultured and the protein is expressed, it can be purified using various chromatography techniques.

Overall, recombinant proteins have revolutionized many areas of biology and medicine, enabling researchers to study and manipulate proteins in ways that were previously impossible.

Chymotrypsin is a proteolytic enzyme, specifically a serine protease, that is produced in the pancreas and secreted into the small intestine as an inactive precursor called chymotrypsinogen. Once activated, chymotrypsin helps to digest proteins in food by breaking down specific peptide bonds in protein molecules. Its activity is based on the recognition of large hydrophobic side chains in amino acids like phenylalanine, tryptophan, and tyrosine. Chymotrypsin plays a crucial role in maintaining normal digestion and absorption processes in the human body.

An amino acid sequence is the specific order of amino acids in a protein or peptide molecule, formed by the linking of the amino group (-NH2) of one amino acid to the carboxyl group (-COOH) of another amino acid through a peptide bond. The sequence is determined by the genetic code and is unique to each type of protein or peptide. It plays a crucial role in determining the three-dimensional structure and function of proteins.

Fibrin is defined as a protein that is formed from fibrinogen during the clotting of blood. It plays an essential role in the formation of blood clots, also known as a clotting or coagulation cascade. When an injury occurs and bleeding starts, fibrin threads form a net-like structure that entraps platelets and red blood cells to create a stable clot, preventing further loss of blood.

The process of forming fibrin from fibrinogen is initiated by thrombin, another protein involved in the coagulation cascade. Thrombin cleaves fibrinogen into fibrin monomers, which then polymerize to form long strands of fibrin. These strands cross-link with each other through a process catalyzed by factor XIIIa, forming a stable clot that protects the wound and promotes healing.

It is important to note that abnormalities in fibrin formation or breakdown can lead to bleeding disorders or thrombotic conditions, respectively. Proper regulation of fibrin production and degradation is crucial for maintaining healthy hemostasis and preventing excessive clotting or bleeding.

Low-molecular-weight heparin (LMWH) is a type of heparin used as an anticoagulant, which refers to a group of medications that prevent the formation of blood clots. Heparin is a naturally occurring substance in the body, and low-molecular-weight heparins are obtained through the depolymerization of standard heparin.

LMWH has a lower molecular weight than standard heparin, which results in several pharmacological differences. LMWHs have a more predictable dose response, longer half-life, and higher bioavailability when administered subcutaneously compared to standard heparin. They also exhibit greater anti-factor Xa activity relative to their antithrombin (anti-IIa) activity, which contributes to their anticoagulant effects.

LMWHs are used for the prevention and treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and other thromboembolic disorders. Common LMWHs include enoxaparin, dalteparin, tinzaparin, and nadroparin.

It is essential to monitor the patient's kidney function when using LMWH since they are primarily cleared by the kidneys. In patients with renal impairment, dose adjustments or alternative anticoagulants may be necessary to reduce the risk of bleeding complications.

Mutations in this gene are associated with heparin cofactor II deficiency. Heparin cofactor II deficiency can lead to increased ... heparin cofactor), member 1". Tollefsen, D M; Majerus, D W; Blank, M K (March 1982). "Heparin cofactor II. Purification and ... 2002). "Contribution of basic residues of the A helix of heparin cofactor II to heparin- or dermatan sulfate-mediated thrombin ... 2004). "Studies on the effect of calcium in interactions between heparin and heparin cofactor II using surface plasmon ...
Heparin cofactor II inhibits arterial thrombosis after endothelial injury Li He, Cristina P. Vicente, Randal J. Westrick, ... He, Li; Vicente, Cristina P.; Westrick, Randal J.; Eitzman, Daniel T.; and Tollefsen, Douglas M., "Heparin cofactor II inhibits ... Daniel T. Eitzman, Douglas M. Tollefsen Published in Volume 109, Issue 2 J Clin Invest. 2002; 109(2):213-219 doi:10.1172/ ...
... heparin cofactor) in man: effects of venous thrombosis and of heparin administration. Eur J Clin Invest. 1977 Feb. 7(1):27-35. ... Two thirds of patients in whom postpartum DVT develops have varicose veins. Thus, in addition to the potential adverse effects ... Protein S is a cofactor for the effect of APC on factors Va and VIIIa. In the United States, the prevalence of heterozygous ... 69] PE was noted to occur in Londoners confined to air raid shelters during World War II. In 1993, Lord and McGrath reported ...
... heparin cofactor II; litm, Ghrhrlit mutation; PCI, protein C inhibitor; PE, pulmonary embolism; pGH, pulsatile GH; TF, tissue ... and heparin cofactor II (HCII) (Serpind1) was significantly higher in female versus male liver, while expression of protein C ... II. A mathematical simulation [erratum 1995, 270:9026]. J. Biol. Chem. 269:23367-23373. View this article via: PubMed Google ... II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br. J. Haematol. 97:785-797. View this ...
Sterile filtered rat plasma with heparin. 0.2 micron. Cat#: BAC61-0050\BAC61-0100\BAC61-0500\BAC61-1000\BAC61-10000. From ... heparin cofactor II precursor (SERPIND1) fragment [Homo sapiens] , TP2256 MSRP: Was: Now: €170.00 - €560.00 ... Sterile filtered rat plasma with heparin. 0.2 micron Sterile filtered rat plasma with heparin. 0.2 micron. Equitech-bio (No ... Sterile filtered rat plasma with heparin. 0.2 micron. Rating * Select Rating. 1 star (worst). 2 stars. 3 stars (average). 4 ...
The interaction of fucoidan with heparin cofactor II, antithrombin III, and thrombin. J Biol Chem 2-25-1989;264:3618-3623. View ... II. Fractionation and partial characterization of the polysaccharide with antitumor activity from Sargassum fulvellum. Jpn.J ... Bell, J., Duhon, S., and Doctor, V. M. The effect of fucoidan, heparin and cyanogen bromide-fibrinogen on the activation of ... 1995;3 Suppl 2:233s-239s. View abstract.. * Ellouali M, Boisson-Vidal C, Durand P, and et al. Antitumor activity of low ...
... except for mucopolysaccharidosis type II, which is X-linked. ... Heparin cofactor II-thrombin complex: a biomarker of MPS ... A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). ... Hunter syndrome (MPS II-B): a report of bilateral vitreous floaters and maculopathy. Ophthalmic Genet. 2006 Jun. 27(2):71-2. [ ... Preventing mucopolysaccharidosis type II (Hunter syndrome): PGD and establishing a Hunter (46, XX) stem cell line. Prenat Diagn ...
APC = activated protein C (APC); AT-III = antithrombin III; FDP = fibrin degradation products; HC-II = heparin cofactor II; ... APC = activated protein C (APC); AT-III = antithrombin III; FDP = fibrin degradation products; HC-II = heparin cofactor II; ... Heparin neutralization is essential for accurate measurement of factor VIII activity and inhibitor assays in blood samples ... Intron 22 of the factor VIII gene, uniquely, contains two other genes. The first gene, F8A, is transcribed in a direction ...
Its anticoagulant activity was due to catalysis of thrombin inhibition by antithrombin but not by heparin cofactor II. ... Specific anticoagulant activity of the purified polysaccharide was 2 IU/mg and its average mass was approximately 160 kDa. The ...
The anticoagulant activity is mainly attributed to thrombin inhibition mediated by heparin cofactor II, with different ... and were potent thrombin inhibitors mediated by heparin cofactor II. They also hastened thrombin and coagulation factor Xa ... Mao W-J, Fang F, Li H-Y, Qi X-H, Sun H-H, Chen Y, Guo S-D (2008) Heparinoid-active two sulfated polysaccharides isolated from ... Two of the five studied fractions showed potent anti-HIV-1 activity both against wild type and drug-resistant HIV-1 strains, ...
The medicinal plant Porana volubilis contains polysaccharides with anticoagulant activity mediated by heparin cofactor II. ... Statistical analysis: Data were expressed as Mean±SEM and analyzed by two-way ANOVA followed by the Bonferroni Test and ... two-way ANOVA and Bonferroni post-test, PE-Cf: Polysaccharide-rich extract of C. ferrea and *p,0.05 vs. saline ... Two-way ANOVA and Bonferroni post-test, PE-Cf: Polysaccharide-rich extract of C. ferrea and *p,0.05 vs. saline ...
Heparin cofactor II * What reaction forms the fibrin polymers in a blood clot ... Why are clotting factors II so important It cuts certain proteins of the clotting cascade activating them, namely Va and Xa. It ... Heparin binds to inactive antithrombin III, after binding it opens the binding site for serine protease, inactivating the ... The inhibition of clot deformation is done by what two agents *Alpha 2 antiplasmin*Plasminogen activator inhibitors (PAI-1 and ...
heparin cofactor II deficiency Alliance Thrombophilia 10 due to heparin cofactor II deficiency. 612356 ... Heparin cofactor II, serpin domain. Serpin, conserved site. Serpin domain. Serpin family. Serpin superfamily. Serpin ... Human ortholog(s) of this gene implicated in heparin cofactor II deficiency. Orthologous to human SERPIND1 (serpin family D ... serpin peptidase inhibitor, clade D (heparin cofactor), member 1 Symbol. serpind1 Nomenclature History Previous Names. *HCII (1 ...
Y. Ikeda, K.-I. Aihara, S. Yoshida et al., "Heparin cofactor II, a serine protease inhibitor, promotes angiogenesis via ... These proteins include astrotactin-1, ADAMTS1, plexin-B1, heparin cofactor 2, Sushi domain-containing protein 2, plasminogen ( ... Y. Hou, P. A. Plett, D. A. Ingram et al., "Endothelial-monocyte-activating polypeptide II induces migration of endothelial ... N. Awasthi, M. A. Schwarz, V. Verma, C. Cappiello, and R. E. Schwarz, "Endothelial monocyte activating polypeptide II ...
Reagents for Heparins and their Analogues Calibrators and Controls Reagents for Direct Xa Inhibitors (DiXaIs) Calibrators and ... Auto-Antibodies to Phospholipid Cofactor Proteins Pathological Markers Anti-β2GP1 Auto-antibodies ... Multi-Calibrators and Controls Activated Factor Specific Calibrators and Controls Heparins and their Analogues Direct Anti-Xa ... Reagents for the detection of Heparin Induced Thrombocytopenia (HIT) ...
Heparin cofactor 2. Taxonomy : Homo sapiens. Nothing to display GlyConnect data is licensed under ...
Heparin cofactor 2. $5.00. USD Add to cart. * Hepatocyte growth factor activator. $5.00. USD Add to cart ... Keratin, type II cytoskeletal 2 epidermal. $5.00. USD Add to cart. * Keratin, type II cytoskeletal 2 oral. $5.00. USD Add to ... Ig kappa chain V-II region 17S29.1. $5.00. USD Add to cart ... Apolipoprotein A-II. $5.00. USD Add to cart. * Apolipoprotein A ... Ig kappa chain V-II region 26-10. $5.00. USD Add to cart ... Keratin, type II cytoskeletal 5. $5.00. USD Add to cart. * ...
O Decreased level of heparin co-factor II,O Decreased level of histidine-rich glycoprotein,O Decreased level of plasminogen,O ... O Type II cryptotia,O Type II diabetes mellitus,O Type II lissencephaly,O Type II transferrin isoform profile,O Type II truncus ... O Two carpal ossification centers present at birth,O Two-raphe bicuspid aortic valve,O Type 1 and type 2 muscle fiber minicore ... O Class II obesity,O Class III obesity,O Claustrophobia,O Clavicular sclerosis,O Clear cell renal cell carcinoma,O Cleft ala ...
Thrombin (IIa)-based assays, in theory, can be falsely elevated by elevated heparin cofactor II because heparin cofactor II is ... A false-positive result for a type II deficiency may occur in the presence of a heparin-binding site (HBS) mutation. Extending ... There are two primary types of antithrombin deficiency: type I and type II. Type I antithrombin deficiency is characterized by ... Another caveat with antithrombin testing involves different type II mutation called antithrombin Cambridge II A384S[15],[16]. ...
KYE28 (KYEITTIHNLFRKLTHRLFRRNFGYT-LR), the representative sequence of helix D of heparin co-factor II, was demonstrated to be ... KYE28 (KYEITTIHNLFRKLTHRLFRRNFGYT-LR), the representative sequence of helix D of heparin co-factor II, was demonstrated to be ... the representative sequence of helix D of heparin co-factor II, was demonstrated to be potent against agronomically important ... The two termini are in close proximity to each other via aromatic packing interactions, whereas the positively charged residues ...
Heparin cofactor 2 (SERPIND1) binds activated thrombin (factor IIa) (Homo sapiens) * SERPIND1 [extracellular region] (Homo ... fibrinogen -> fibrin monomer + 2 fibrinopeptide A + 2 fibrinopeptide B (Homo sapiens) * Extracellular thrombin inactivating ... factor XIII -> factor XIII cleaved tetramer + 2 factor XIII A activation peptides (Homo sapiens) * Extracellular thrombin ...
called the waterfall or cascade model of coagulation and led to the term "the coagulation cascade". Heparin cofactor II: This ... Anticoagulation with heparin for CPB depends on AT to inhibit clotting as heparin, alone, has no effect on coagulation. Heparin ... Heparin depends on antithrombin as a cofactor 7 coagulation cascade occurred due to introduction of a cell based model which ... Informations hemostasis and heparin Hématologie, Sentiers, Science, Santé. hemostasis and heparin.. hepatic. hepatitis/M. ...
glycoprotein I protects thrombin from inhibition by heparin cofactor II: Potentiation of this effect in the presence of anti-β ... 2. -glycoprotein I, Proceedings of the National Academy of Sciences of the United States of America, 101, pp. 3939 - 3944, ... 2. - glycoprotein i potentiates the lupus autoimmune phenotype in a toll-like receptor 7-mediated murine model, Arthritis and ... Passam F; Qi JC; Tanaka K; Matthaei K; Krilis S, 2010, In vivo modulation of angiogenesis by beta 2 glycoprotein I., Journal ...
Antithrombin (Heparin cofactor II). carrier proteins:. *alpha-1 (Transcortin). *alpha-2 (Ceruloplasmin) ... In humans and most mammals, an antibody unit consists of four polypeptide chains; two identical heavy chains and two identical ... Schematic structure of an antibody: two heavy chains (blue, yellow) and the two light chains (green, pink). The antigen binding ... "if two substances give rise to two different Antikörper, then they themselves must be different".[60] However, the term was not ...
author keywords: molecular evolution; serpins; exon-intron structure; diagnostic sites; heparin cofactor II ...
Heparin cofactor II. 66. 90. Protease inhibitor. Protein C*. 62. 4. Protease zymogen. ... The activity of APC is potentiated by two cofactors, protein S and native (non-activated) factor V. Protein S functions as a ... by activating platelets and the two circulating non-enzymatic cofactor proteins, factor V and factor VIII.22-23 All these ... cofactor activity, whereas cleavage at Arg679 is lipid-independent and is responsible for the loss of the remaining cofactor ...
Heparin Cofactor II. 66. 80. 1.2. Plasmin Inhibitor. 63. 60. 1. Protein C Inhibitor. 57. 4. 0.07. ... which gives rise to a two-chain molecule linked by two disulfide bonds. tPA binding to fibrin concentrates and correctly ... Dysplasminogenemia, or type II, is characterized by a reduced activity/antigen ratio, meaning that the activity level is more ... There are two types of hereditary plg deficiency. Hypoplasminogenemia, also called type I, is characterized by a parallel ...
... heparin cofactor) in man: effects of venous thrombosis and of heparin administration. Eur J Clin Invest. 1977 Feb. 7(1):27-35. ... Two thirds of patients in whom postpartum DVT develops have varicose veins. Thus, in addition to the potential adverse effects ... Protein S is a cofactor for the effect of APC on factors Va and VIIIa. In the United States, the prevalence of heterozygous ... 69] PE was noted to occur in Londoners confined to air raid shelters during World War II. In 1993, Lord and McGrath reported ...
APC = activated protein C (APC); AT-III = antithrombin III; FDP = fibrin degradation products; HC-II = heparin cofactor II; ... APC = activated protein C (APC); AT-III = antithrombin III; FDP = fibrin degradation products; HC-II = heparin cofactor II; ... Heparin neutralization is essential for accurate measurement of factor VIII activity and inhibitor assays in blood samples ... Intron 22 of the factor VIII gene, uniquely, contains two other genes. The first gene, F8A, is transcribed in a direction ...
Heparin cofactor II. "Entrez Gene: SERPIND1 serpin peptidase inhibitor, clade D (heparin cofactor), member 1". Tollefsen, D M; ... Heparin Cofactor II. A sulfated plasma protein with a MW of approximately 66kDa that resembles ANTITHROMBIN III. The protein is ... Serpin D1 / Heparin cofactor II. Serum Amyloid A. Serum amyloid P component. .... ... Antithrombin III-Alpha Atenativ Heparin Co-Factor I Heparin Cofactor .... ...

No FAQ available that match "heparin cofactor ii"

No images available that match "heparin cofactor ii"